Deaths, accusations of insider trading and an early warning from Boehringer stir Hanmi controversy
Controversy over a lethal cancer drug developed by Hanmi and Boehringer Ingelheim continues to bubble up in Korea.
In recent days a member of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
